Overview

Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer

Status:
RECRUITING

Trial end date:
2029-10-01

Target enrollment:

Participant gender:

Summary

The goal of this clinical study is to learn more about the study drug sacituzumab govitecan (SG; Trodelvy; GS-0132; IMMU 132), versus standard of care (SOC) in participants with previously treated extensive stage small cell lung cancer (ES-SCLC). The primary objectives of this study are to compare the effect of SG to SOC on objective response rate (ORR) as assessed by blinded independent central review (BICR) according to the Response Evaluation Criteria in Solid Tumors and to compare the effect of SG to SOC on overall survival (OS).

Phase:

PHASE3

Details

Lead Sponsor:

Gilead Sciences

Treatments:

amrubicin
sacituzumab govitecan
Topotecan